Johnson & Johnson partners with Sail Biomedicines to push in vivo CAR-T efforts for autoimmune disease

Johnson & Johnson said it has entered strategic agreements and a collaboration with Sail Biomedicines, a biotechnology company working on in vivo CAR-T therapies, in an effort that the companies framed as a potential path to treating autoimmune disease through an “immune reset.” The announcement was reported July 29 by Yahoo Finance.

CAR-T, or chimeric antigen receptor T-cell therapy, is a form of immunotherapy that engineers a patient’s immune cells to recognize and attack specific targets. In vivo CAR-T refers to strategies designed to generate or activate the CAR-T effect inside the body rather than manufacturing the cells ex vivo and returning them to the patient, a distinction that can materially affect development timelines, logistics, and how researchers manage safety and effectiveness.

In the update, Johnson & Johnson linked the Sail collaboration to its plans to advance in vivo CAR-T programs and address autoimmune disease. The companies described the science theme as an immune reset, an approach aimed at rebalancing the immune system rather than simply suppressing symptoms, though specific mechanisms and target populations were not detailed in the report.

The announcement highlighted “strategic agreements” as well as the collaboration itself, but it did not disclose in the Yahoo Finance post what the commercial terms include, such as funding levels, milestone schedules, or whether Johnson & Johnson has options to acquire rights in later stages of development.

Sail Biomedicines is positioned in the update as a developer of in vivo CAR-T therapies, indicating the partnership is likely intended to combine Sail’s platform work with Johnson & Johnson’s late-stage development, clinical development scale, and therapeutic-area reach. Johnson & Johnson has a broad healthcare portfolio, and immunology remains one of its key focus areas as it seeks treatments for conditions where long-term disease control is difficult.

For Johnson & Johnson, deals like this also function as a hedge against uncertainty in cell therapy. While CAR-T has shown promise in certain blood cancers, autoimmune applications and in vivo approaches are still in earlier phases compared with more established, tumor-focused CAR-T workflows. A partnership can spread technical risk, accelerate access to platform capabilities, and create multiple shots on goal if early safety and efficacy indicates emerge.

One limitation of the July 29 report is that it does not provide program-level specifics. The companies did not specify which autoimmune diseases they are targeting in this collaboration, whether any IND-enabling activities or first-in-human studies are already planned, or what endpoints they expect to track. The update also does not state the timing of major milestones, the stage of development for the programs, or which party will lead particular research workstreams.

What to watch next is whether Johnson & Johnson and Sail provide further details on the clinical roadmap and the scientific rationale for the immune reset concept in autoimmune settings. Investors and industry observers will likely look for disclosures about target indications, trial design principles for in vivo CAR-T, and any milestone structure that could indicate how the companies plan to manage both development risk and long-term commercialization.